Results of the votes of the Combined Shareholders’ General Meeting
of January 25, 2023
Daix (France), Long Island City (New
York, United States), January 26, 2023 – Inventiva
(Euronext Paris and Nasdaq: IVA), a clinical-stage
biopharmaceutical company focused on the development of oral small
molecule therapies for the treatment of non-alcoholic
steatohepatitis (NASH) and other diseases with unmet medical need,
today announced the results of the votes of its Combined
Shareholders’ General Meeting.
The Combined Shareholders' Meeting was held on
January 25, 2023 at 2 p.m. at Hôtel Oceania Le Jura, 14 avenue
Foch, 21000 Dijon (France), under the chairmanship of Mr. Frédéric
Cren, Chairman and Chief Executive Officer and cofounder of
Inventiva.
Mr. Frederic Cren proceeded to the usual
formalities of the opening of the meeting, in particular to the
constitution of the Bureau by appointing Mr. Pierre Broqua and Mr.
Jean Volatier, as tellers, as well as Mr. Eric Duranson, as
secretary of the general meeting.
All the resolutions submitted to vote have been
adopted by the shareholders, with the exception of the eleventh, as
recommended by the Board of Directors.
Information on the results of the votes is
detailed below:
- Total number of shares composing the share capital: : 42 134
169
- Total number of shares with voting rights: 42 027 480
|
Ordinary part |
Extraordinary part |
Shareholders |
Shares |
Votes |
Shareholders |
Shares |
Votes |
|
Shareholders present |
0 |
0 |
0 |
0 |
0 |
0 |
|
Proxy to third parties |
0 |
0 |
0 |
0 |
0 |
0 |
|
Proxy to the Chairman |
119 |
2 060 712 |
2 188 682 |
119 |
2 060 712 |
2 188 682 |
|
Mail votes |
84 |
24 451 455 |
36 586 555 |
84 |
24 451 455 |
36 586 555 |
|
TOTAL |
203 |
26 512 167 |
38 775 237 |
203 |
26 512 167 |
38 775 237 |
|
Quorum |
63,082 % |
63,082 % |
VOTE RESULTSOrdinary Resolutions
|
Resolution |
Result |
For |
Against |
Abstention |
Total number of votes cast |
Number of represented shares |
Proportion of represented share capital |
Quorum |
Votes |
% |
Votes |
% |
Votes |
% |
1 |
Adopted |
38 758 418 |
99.96 % |
15 859 |
0.04 % |
960 |
- |
38 774 277 |
26 512 167 |
62.923 % |
63.082 % |
16 |
Adopted |
38 755 524 |
99.95 % |
18 504 |
0.05 % |
1 209 |
- |
38 774 028 |
26 512 167 |
62.923 % |
63.082 % |
VOTE RESULTSExtraordinary
Resolutions |
Resolution |
Result |
For |
Against |
Abstention |
Total number of votes cast |
Number of represented shares |
Proportion of represented share capital |
Quorum |
Votes |
% |
Votes |
% |
Votes |
% |
2 |
Adopted |
35 614 593 |
91.85 % |
3 160 114 |
8.15 % |
530 |
- |
38 774 707 |
26 512 167 |
62.923 % |
63.082 % |
3 |
Adopted |
35 607 497 |
91.83 % |
3 167 160 |
8.17 % |
580 |
- |
38 774 657 |
26 512 167 |
62.923 % |
63.082 % |
4 |
Adopted |
35 605 052 |
91.83 % |
3 169 505 |
8.17 % |
680 |
- |
38 774 557 |
26 512 167 |
62.923 % |
63.082 % |
5 |
Adopted |
35 605 302 |
91.83 % |
3 169 355 |
8.17 % |
580 |
- |
38 774 657 |
26 512 167 |
62.923 % |
63.082 % |
6 |
Adopted |
35 605 466 |
91.83 % |
3 169 090 |
8.17 % |
681 |
- |
38 774 556 |
26 512 167 |
62.923 % |
63.082 % |
7 |
Adopted |
35 606 951 |
91.83 % |
3 167 646 |
8.17 % |
640 |
- |
38 774 597 |
26 512 167 |
62.923 % |
63.082 % |
8 |
Adopted |
35 607 577 |
91.83 % |
3 167 181 |
8.17 % |
479 |
- |
38 774 758 |
26 512 167 |
62.923 % |
63.082 % |
9 |
Adopted |
35 608 177 |
91.83 % |
3 166 430 |
8.17 % |
630 |
- |
38 774 607 |
26 512 167 |
62.923 % |
63.082 % |
10 |
Adopted |
35 608 127 |
91.83 % |
3 166 280 |
8.17 % |
830 |
- |
38 774 407 |
26 512 167 |
62.923 % |
63.082 % |
11 |
Rejected |
10 448 947 |
26.95 % |
28 325 160 |
73.05 % |
1 130 |
- |
38 774 107 |
26 512 167 |
62.923 % |
63.082 % |
12 |
Adopted |
38 751 168 |
99.94 % |
23 539 |
0.06 % |
530 |
- |
38 774 707 |
26 512 167 |
62.923 % |
63.082 % |
13 |
Adopted |
35 608 520 |
91.84 % |
3 164 553 |
8.16 % |
2 164 |
- |
38 773 073 |
26 512 167 |
62.923 % |
63.082 % |
14 |
Adopted |
35 606 496 |
91.83 % |
3 167 922 |
8.17 % |
819 |
- |
38 774 418 |
26 512 167 |
62.923 % |
63.082 % |
15 |
Adopted |
35 602 218 |
91.82 % |
3 171 900 |
8.18 % |
1 119 |
- |
38 774 118 |
26 512 167 |
62.923 % |
63.082 % |
About Inventiva
Inventiva is a clinical-stage biopharmaceutical
company focused on the research and development of oral small
molecule therapies for the treatment of patients with NASH,
mucopolysaccharidoses (MPS) and other diseases with significant
unmet medical needs. The Company benefits from a strong expertise
and experience in the domain of compounds targeting nuclear
receptors, transcription factors and epigenetic modulation.
Inventiva is currently advancing one clinical candidate, has a
pipeline of two preclinical programs and continues to explore other
development opportunities to add to its pipeline.
Inventiva’s lead product candidate,
lanifibranor, is currently in a pivotal Phase III clinical trial,
NATiV3, for the treatment of adult patients with NASH, a common and
progressive chronic liver disease for which there are currently no
approved therapies. In 2020, Inventiva reported positive results
from its Phase IIb clinical trial evaluating lanifibranor for the
treatment of patients with NASH and received Breakthrough Therapy
and Fast Track status from the U.S. Food and Drug Administration
(“FDA”) for lanifibranor in the treatment of NASH.
Inventiva’s pipeline also includes odiparcil, a
drug candidate for the treatment of adult MPS VI patients. As part
of Inventiva’s decision to focus clinical efforts on the
development of lanifibranor, it suspended its clinical efforts
relating to odiparcil and is reviewing available options with
respect to its potential further development. Inventiva is in the
process of selecting an oncology development candidate for its
Hippo signaling pathway program.
The Company has a scientific team of
approximately 80 people with deep expertise in the fields of
biology, medicinal and computational chemistry, pharmacokinetics
and pharmacology, and clinical development. It owns an extensive
library of approximately 240,000 pharmacologically relevant
molecules, approximately 60% of which are proprietary, as well as a
wholly-owned research and development facility.
Inventiva is a public company listed on
compartment C of the regulated market of Euronext Paris (ticker:
IVA - ISIN: FR0013233012) and on the Nasdaq Global Market in the
United States (ticker: IVA). www.inventivapharma.com.
Contacts
Inventiva Pascaline ClercVP of Global External
Affairsmedia@inventivapharma.com +1 240 620
9175 |
Brunswick GroupTristan Roquet Montegon /Aude
Lepreux /Matthieu BenoistMedia
relationsinventiva@brunswickgroup.com +33 1 53 96 83
83 |
Westwicke, an ICR CompanyPatricia L. BankInvestor
relationspatti.bank@westwicke.com
+1 415 513-1284 |
|
|
|
|
|
|
Important Notice
This press release contains “forward-looking
statements” within the meaning of the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. All statements,
other than statements of historical facts, included in this press
release are forward-looking statements. These statements include,
but are not limited to, Inventiva’s pipeline and preclinical and
clinical development plans, future activities, expectations, plans,
growth and prospects of Inventiva and its product candidates.
Certain of these statements, forecasts and estimates can be
recognized by the use of words such as, without limitation,
“believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”,
“estimates”, “may”, “will”, “would”, “could”, “might”, “should”,
and “continue” and similar expressions. Such statements are not
historical facts but rather are statements of future expectations
and other forward-looking statements that are based on management's
beliefs. These statements reflect such views and assumptions
prevailing as of the date of the statements and involve known and
unknown risks and uncertainties that could cause future results,
performance or future events to differ materially from those
expressed or implied in such statements. Future events are
difficult to predict and may depend upon factors that are beyond
Inventiva's control. There can be no guarantees with respect to
pipeline product candidates that the clinical trial results will be
available on their anticipated timeline, that future clinical
trials will be initiated as anticipated, that product candidates
will receive the necessary regulatory approvals. Actual results may
turn out to be materially different from the anticipated future
results, performance or achievements expressed or implied by such
statements, forecasts and estimates, due to a number of factors,
including that Inventiva is a clinical-stage company with no
approved products and no historical product revenues, Inventiva has
incurred significant losses since inception, Inventiva has a
limited operating history and has never generated any revenue from
product sales, Inventiva will require additional capital to finance
its operations, Inventiva's future success is dependent on the
successful clinical development, regulatory approval and subsequent
commercialization of current and any future product candidates,
preclinical studies or earlier clinical trials are not necessarily
predictive of future results and the results of Inventiva's
clinical trials may not support Inventiva's product candidate
claims, Inventiva may encounter substantial delays in its clinical
trials or Inventiva may fail to demonstrate safety and efficacy to
the satisfaction of applicable regulatory authorities, enrolment
and retention of patients in clinical trials is an expensive and
time-consuming process and could be made more difficult or rendered
impossible by multiple factors outside Inventiva's control,
Inventiva's product candidates may cause adverse drug reactions or
have other properties that could delay or prevent their regulatory
approval, or limit their commercial potential, Inventiva faces
substantial competition and Inventiva’s business, and preclinical
studies and clinical development programs and timelines, its
financial condition and results of operations could be materially
and adversely affected by the current COVID-19 pandemic and
geopolitical events, such as the conflict between Russia and
Ukraine, related sanctions and related impacts and potential
impacts on the initiation, enrolment and completion of Inventiva’s
clinical trials on anticipated timelines and macroeconomic
conditions, including global inflation and uncertain financial
markets or at all. Given these risks and uncertainties, no
representations are made as to the accuracy or fairness of such
forward-looking statements, forecasts and estimates. Furthermore,
forward-looking statements, forecasts and estimates only speak as
of the date of this press release. Readers are cautioned not to
place undue reliance on any of these forward-looking
statements.
Please refer to the Universal Registration
Document for the year ended December 31, 2021 filed with the
Autorité des Marchés Financiers on March 11, 2022, the Annual
Report on Form 20-F for the year ended December 31, 2021 filed with
the Securities and Exchange Commission on March 11, 2022 and the
financial report for the first half of 2022 filed with the
Securities and Exchange Commission on September 22, 2022 for
additional information in relation to such factors, risks and
uncertainties.
All information in this press release is as of
the date of the release. Except as required by law, Inventiva has
no intention and is under no obligation to update or review the
forward-looking statements referred to above.
- Inventiva - PR - Results AG 2023 - EN - 26 01 2023
Inventiva (EU:IVA)
Historical Stock Chart
From Sep 2024 to Oct 2024
Inventiva (EU:IVA)
Historical Stock Chart
From Oct 2023 to Oct 2024